ArticleCancer biology & therapy2014

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

Seiichi Okabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.